All In Biotech

Drug Trial Radar · NCT06183931

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,182 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,182

Actual

Start

Jan 11, 2024

Primary completion

Dec 6, 2027

Study completion Apr 5, 2028

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.

Conditions

  • Transthyretin Amyloid Cardiomyopathy

Interventions

  • ALXN2220Drug

    Participants will receive ALXN2220 via IV infusion.

  • PlaceboDrug

    Participants will receive placebo via IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Occurrence of ACM and CV clinical events during the Blinded Treatment PeriodTime frame: Baseline up to the end of study (up to Month 48)

Locations

213 sites in 27 countries. Site status is shown where the registry gives one.

  • Research Site

    Irvine, California

  • Research Site

    La Jolla, California

  • Research Site

    Palo Alto, California

  • Research Site

    San Francisco, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Jacksonville, Florida

  • Research Site

    Weston, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Kansas City, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Stony Brook, New York

  • Research Site

    Chapel Hill, North Carolina

  • Research Site

    Durham, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Danville, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Charleston, South Carolina

  • Research Site

    Greenville, South Carolina

  • Research Site

    Memphis, Tennessee

  • Research Site

    Fort Worth, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Falls Church, Virginia

  • Research Site

    Richmond, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Madison, Wisconsin

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

Showing 40 of 213 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.